A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Masuishi, T. [1 ]
Sakai, Y. [1 ]
Matsui, T. [1 ]
Nakamura, R. [1 ]
Anzai, S. [1 ]
Suzuki, Y. [1 ]
Kobori, I. [1 ]
Fukami, Y. [1 ]
Suzuki, K. [1 ]
Tazawa, J. [1 ]
机构：
[1] Tsuchiura Kyodo Gen Hosp, Dept Gastroenterol, Tsuchiura, Ibaraki, Japan
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The impact of toxicity and efficacy on quality of life in KRAS wild-type metastatic colorectal cancer patients treated with first-line chemotherapy plus cetuximab
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Von Hohnhorst, P.
    Esser, R.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S518 - S518
  • [42] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [43] A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
    Hazama, Shoichi
    Maeda, Hiromichi
    Iwamoto, Shigeyoshi
    Kim, Ho Min
    Takemoto, Hiroyoshi
    Kobayashi, Kenji
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    Clinical Colorectal Cancer, 2016, 15 (04) : 329 - 336
  • [44] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [45] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
  • [46] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [47] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    BMC Cancer, 15
  • [48] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [49] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Shigenori Kadowaki
    Toshiki Masuishi
    Takashi Ura
    Keiji Sugiyama
    Seiichiro Mitani
    Yukiya Narita
    Hiroya Taniguchi
    Kei Muro
    International Journal of Clinical Oncology, 2021, 26 : 701 - 707
  • [50] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Ura, Takashi
    Sugiyama, Keiji
    Mitani, Seiichiro
    Narita, Yukiya
    Taniguchi, Hiroya
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 701 - 707
12345